chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pt presented to vaccination site and requested Janssen COVID vaccine booster dose. Patient received Sinovac 1st dose on 3/11/21 and Sinovac 2nd dose 4/9/21. RN 1 educated patient on health risks of Janssen COVID vaccine. Patient verbalized understanding and requested Janssen COVID vaccine booster dose. RN 1 submitted a medical consult via Patient presented to vaccination site and requested Janssen COVID-19 vaccine booster dose. Patient received Pfizer 1st dose on 3/26/21 and Pfizer 2nd dose 4/14/21. RN 1 educated patient on health risks of Janssen COVID-19 vaccine. Patient verbalized understanding and requested Janssen COVID-19 vaccine booster dose. RN 1 submitted a medical consult via collaboration app to clinical project coordinators requesting to proceed with Janssen COVID-19 vaccine. Clinical project coordinator RN 2 elevated request to medical consult team. MD 1 from medical consult team approved request for Janssen COVID-19 vaccine booster dose. On 3/21/21, patient received Janssen COVID-19 vaccine (lot 1855191) booster dose at 1359. EMT 1 educated patient on signs and symptoms of adverse reactions, when to seek emergency care, and to register on v-safe. At approximately 1415, patient left facility with unlabored respirations and steady gait. to Clinical Project Coordinators requesting to proceed with Janssen COVID vaccine. Clinical Project Coordinator RN 2 elevated request to medical consult team. MD 1 from medical consult team approved request for Janssen COVID vaccine booster dose. On 3/21/22, patient received Janssen COVID vaccine (LOT# 1855191) booster dose at 1401. EMT 1 educated patient on signs and symptoms of adverse reactions, when to seek emergency care, and to register on V-Safe. At approximately 1415, patient left facility with unlabored respirations and steady gait.
pt recvd vax 7JUL93 & 14OCT93 pt devel clinical rubella; devel morbilliform rash from face to chest, hard posterior occipital node, fever for 3 days & upper resp infect; lab eval 17NOV93 revealed rubella antibody 2.12 & rubeola IGG 0.27;
Leg pain, HTN, Clotting factor mutation, Headaches, Palpatations
Client was vaccinated on 2/3/2021 and 3/3/2021 for Covid-19 and tested positive on 6/11/2021.  Client is asymptomatic.  Sample will be sent for genomic sequencing.
NO ADVERSE EFFECT AT ALL.  AT THE TIME OF VACCINATION PATIENT WAS 16+ YEARS OLD.  PATIENT GOT 1ST FULL DOSE, & SECOND DOSE 1/2 DOSE .  EXPLEINED TO PATIENT & MOTHER THAT SHE DOES NOPT NEED SECOND DOSE, MOTHER INSISTED TO GIVE OT ANY WAY. 1/2 DOSE WAS GIVEN. PATIENT CAME FOR BOOSTER DOSE, & i REFUSED THE BOOSTER DOSE TO OATIENT & EX[PLAINED IT TO PATIENT & MOTHER . BOTH SEEMED TO BE SATISFIED BUT STILL WANTED A BOOSTER SHOT.
Patient had swelling of the throat (lump in throat) approximately six hours after receiving the vaccinations.
Bruising easily, petechiae.  Likely idiopathic thrombocytopenic purpura.
had reaction with first dose; This case was reported by a consumer and described the occurrence of adverse drug reaction in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced adverse drug reaction. On an unknown date, the outcome of the adverse drug reaction was recovered/resolved.   It was unknown if the reporter considered the adverse drug reaction to be related to Shingrix.  Additional case details were reported as follows: The age at vaccination was not reported. The age group was not reported, but was selected adult as per vaccine indication. The patient had reaction with first dose lasting for 2 days. The reporter requesting consent to follow up. For tolerance of 2nd dose refer case US2020AMR053971.
Pt exp rashes, fevers, numbness & tingling in arms & legs, sore throat, joint & muscle pains, in fingers & toes also, h/a, chest pains severe @ times;
I have been menopausal for almost two years and two days post second dose began spotting. It only happened for the one day but I thought someone should know to have on record as I am hearing that I am not the only one.
This is a spontaneous report from a contactable pharmacist received via a Pfizer sales representative. An elderly female patient received PREVNAR 13 (lot number and expiration date unknown), via an unspecified route of administration on 14Aug2018 at a single dose for immunization. The patient's medical history and concomitant medications were not reported. The patient experienced rash extending from injection site towards the neck on 14Aug2018. The outcome of the event was unknown. Information on the batch/lot number has been requested.
Became ill w/in 6-7 hrs p/immun; sx congestion, cough, pain in chest, lt arm; Seen by MD 10DEC91 has asthma;
Patient had no symptoms for 3 weeks.  Then he developed an abscess at the injection site.  It was red and swollen with a hard nodule under the skin.  Pus came out from abscess at home with no intervention; patient sought follow up with PCP a few days later.  Area was still swollen with a visible scab at injection site. Patient is spanish-speaking only.
Chills, fever, aching, loss of appetite, tired, upset stomach for approximately 27 hours.
Headache, Myalgia & Nausea Vomiting  Narrative:
pt recv vax & 1/2 hr post vax pt exp disorientation, visual disturbances (moving field of vision), inability to concentrate & loss of coordination;these sx lasted 6 hr & resolved untreated;
pt recvd vax 29OCT93 & on 30OCT93 started itching w/welts; pt put on cortisone cream w/some relief; itching seems worse 2NOV93; referred to MD;
sz x 2 1AUGu92; initial sz witnessed by mom eyes rolled back & shaking all over; 2nd sz seen by RN eyes rolled back, extremities rigid;
hardness at the injection site; itchiness. and hardness at the injection site; heaviness in the injected arm; sweating at her hairline; feeling of being hot; pain, redness and swelling at the injection site; redness and swelling at the injection site; swelling at the injection site; tiredness; muscle aches; feeling feverish; This case was reported by a nurse via call center representative and described the occurrence of injection site pain in a 59-year-old female patient who received Herpes zoster (Shingrix) (batch number 54H72, expiry date 1st October 2021) for prophylaxis.   On 19th September 2020 13:00, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. In September 2020, less than a day after receiving Shingrix, the patient experienced tiredness, muscle pain and fever. On 19th September 2020, the patient experienced injection site pain, injection site erythema and injection site swelling. On 20th September 2020, the patient experienced injection site induration, injection site itching, heaviness in arm, sweating and feeling hot. On an unknown date, the outcome of the injection site pain, injection site erythema, injection site swelling, injection site induration, injection site itching, tiredness, muscle pain, fever, heaviness in arm, sweating and feeling hot were not recovered/not resolved.   It was unknown if the reporter considered the injection site pain, injection site erythema, injection site swelling, injection site induration, injection site itching, tiredness, muscle pain, fever, heaviness in arm, sweating and feeling hot to be related to Shingrix.  Additional details were reported as follows: This case was reported by patient for herself. On Saturday at 01:00 pm, the patient received Shingrix on right arm. In the evening, less than a day after receiving Shingrix, the patient experienced pain, redness and swelling at the injection site. The patient experienced tiredness, muscle aches and felt feverish in the early hours of Sunday morning. One day after receiving Shingrix, the patient experienced heaviness in the injected arm and the itchiness and hardness at the injection site. A day before reporting, the patient also had sweating at her hairline and an overall feeling of being hot. The reporter consented to follow up.
On day 7 (Friday)after receiving the shot I woke up with my injection site being really itchy.  Mid day, I developed a small red rash and by end of day it grew almost double the original size.  I was feeling real tired and had a headache majority of the day.  I took Ibuprofen and it didn?t seem to help.  The next day, Saturday, I woke up and the rash had gotten bigger and my arm was swollen and very warm and it was really firm in the area where it was red. There was a constant uncomfortable feeling coming from the site.  Continue to have headaches and felt very tired   Sunday, The next day the rash was there but it was smaller and the swelling went down. Then on Monday I went back to the urgent care where she prescribed me a steroid pack and some itch cream.  Use the edge cream that day but it seem to make it worse and started the steroid pack on Tuesday. On Tuesday,  which is today my arm started flaring up again really bright red itchy and uncomfortable feeling.  I also became really tired and got headache sagain. Took ibuprofen and continue to take steroid steroid pack
Breakthrough case admission after 2 vaccines Moderna 2/9/21 Lot# 038K20A;  Moderna 3/9/21 Lot# 030A21A
Fever ( 100 degrees), body aches, headahce, sore throat, and runny nose.  On 10/28/09 was seen by provider and diagnosed with bronchitis.  Started on azithromycin
unilateral L cervical lymphadenopathy x 6 weeks, also includes ? in L submandibular, L post auricular areas. Now receiveiving more extensive work up to rule out other cause.
This spontaneous report as received from a Medical Assistant refers to a 1 year old female patient. The patient did not have concurrent conditions. The patient's historical drugs and historical conditions were not reported. On 30-OCT-2017, the patient was vaccinated with PROQUAD (also reported as M-M-R II, conflicting information) lot # N019827, expiration date 09-JAN-2017, dose 1, subcutaneous in the left thigh for prophylaxis, instead M-M-R II (wrong drug administered) due to preparation and administration error. On the same date, the patient also received VARIVAX lot number N019822, expiration date 13-JUL-2019, subcutaneous in the right thigh for prophylaxis (overdose), and sterile diluent lot number M009799, expiration date 11-SEP-2018 (dose, route and indication were not reported). Concomitant therapies included PEDVAXHIB, PREVNAR and influenza virus vaccine (unspecified). No adverse events were reported. The patient did not receive treatment.
C/o pain and mild swelling of upper right arm. Provider massaged and did ROM to arm. Warm, moist heat applied. No redness or hives.
two doses of Pfizer and the received two doses of Moderna.; body ache; fatigue; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (body ache), FATIGUE (fatigue) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (two doses of Pfizer and the received two doses of Moderna.) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014C21A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Pfizer from 24-Jan-2021 to 13-Feb-2021. Past adverse reactions to the above products included Vaccination site tenderness with Pfizer. Concurrent medical conditions included Immunosuppression NOS. Concomitant products included METFORMIN, GABAPENTIN, CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]), LISINOPRIL, TRAZODONE, ACETYLSALICYLIC ACID (BABY ASPIRIN), ESCITALOPRAM OXALATE (LEXAPRO), ATORVASTATIN and CERTOLIZUMAB PEGOL (CIMZIA) for an unknown indication.    On 13-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYALGIA (body ache), FATIGUE (fatigue) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (two doses of Pfizer and the received two doses of Moderna.). At the time of the report, MYALGIA (body ache), FATIGUE (fatigue) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (two doses of Pfizer and the received two doses of Moderna.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Treatment was received.   This case was linked to MOD-2021-355797 (Patient Link).
Started with a headache, chills and very tired. She stated she had an uneasy and confused feeling.Pain in her stomach. She started to have alot of itching sensation on her stomach, legs and by her private parts. She notice rashes started to appear. She put Cortisone on the rashes. The rashes has since moved all over her body. She said now the started to look like Shingle clusters turned red and pink.
Seizure on 09-26-09. 10/15/2009 received hospital records for date 9/27/2009. Patient left hospital approx 2 hours later without seeing MD or getting any Tx.  10/15/09:  Hospital records receiced for date of service 9/27/09 Assessment:  Pt. presented with HA pain 4/10.  VSS, left before seeing MD.  No mention of seizure in records.  10/16/2009 received Immunization Records.
I took my 9 month old baby to the doctor's office strictly for an immunization nurse visit. She should have received DTaP, Hib and IPV. The nurse walked into the room and stated she confused the Hib with Hep B, mistakenly thinking Hib was part of the DTaP shot and then stated that my daughter would receive 3 shots instead of two. I already knew she should receive 3 shots. I later received a call that the nurse mistakenly administrated Hepatitis B instead of Hib.
One week after receiving vaccination, the site of the injection became red, raised, and very itchy. I took antihistamine over the counter and that does help alleviate the discomfort.
flushing  severe back aches kidney pain sever jant pain (elbow) wrist hands; knees headache
The initial injection was uneventful, with only slight pain for 2 days.  However, on day 8, a hard swollen red area, about 2 inches in diameter, appeared below the injection site.  It was initially itchy.  It responded well to ice, and gradually diminished over the next 3 days.
Body aches, dizziness, insomnia related to the pain, nausea, weakness, restlessness, headache, injection site pain, chest pains.
decedent had shortness of breath and hypoxia, cardiac arrested in front of the EMS crew, ACLS initiated, arrived in the  Hospital ED asystole and pronounced dead
I broke out in full-body hives; Extremely itchy and painful, even spread to my face; Extremely itchy and painful; mixture of hives and eczema; have otherwise caused this rash; This is a spontaneous report from a contactable consumer.  A 21-years-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot Number: EN6207), dose 1 via an unspecified route of administration, administered in Arm Left on 10Mar2021 (at the age of 21-years-old ) as dose 1, single for covid-19 immunisation. Medical history included Hashimoto's disease and Diflucan Allergy. Concomitant medication included levothyroxine sodium (SYNTHROID), Birth control and pre/probiotics.  On 04Apr2021, the patient experienced i broke out in full-body hives, extremely itchy and painful, even spread to my face, extremely itchy and painful, mixture of hives and eczema, have otherwise caused this rash. The patient underwent lab tests and procedures which included sars-cov-2 test: negative on 07May2021 covid test type post vaccination: Nasal Swab. Treatment with steroids and antihistamines was given for the events. The patient received the 2nd dose of the vaccine (Lot number: ER8731) on 21Apr2021 in left arm for covid-19 immunisation. The patient received no other vaccine in four weeks. 3 weeks following the first dose, the patient broke out in full-body hives. Extremely itchy and painful, even spread to her face. Now, four months later, she was still suffering flare-ups of a mixture of hives and eczema that cover her stomach, legs, neck, and arms. She had seen several doctors to rule out allergies, autoimmune etc that might have otherwise caused this rash. There are still no concrete results on why the rash was persisting. AE resulted in doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care. The patient was not COVID prior vaccination. The patient tested covid post vaccination. Outcome of the events were not recovered.   Follow-up (24Aug2021): Follow-up attempts are completed. No further information is expected.
Information has been received from a registered nurse concerning a 19 week old infant who was vaccinated on 27-DEC-2006 with an oral dose of Rotateq. No problems were reported. It was not reported if medical attention was sought. There was no product quality complaint involved. Additional information is not expected.
w/in min of being immun, pt noted redness & discomfort @ inject site; W/in 4 days developed a large red raised hot area @ same site; By 1wk developed 5x7 1/2CM abscess which was drained; Tx antibiotics;
Received Tdap vaccine 2/10/06, 10-12 hours later had shooting pain in left arm.  Felt better next day.  Then Tuesday 2-14-06 had severe pain in fromt left armpit and chest. Has treated with ibuprofen and lidocaine patch. Call to doctor and told to continue as doing 2/21/06.
the connection between the antigen vial and diluent syringe not going well; other Abrysvo vaccines that had the connection between the antigen vial and diluent syringe not going well/ those were all administered to patients; This is a spontaneous report received from a contactable reporter(s) (Pharmacist) from product quality group.  A patient (no qualifiers provided) received rsv vaccine prot.subunit pref 2v (ABRYSVO), as dose number unknown,single (Lot number: HF5020, Expiration Date: Feb2025) for immunisation; for immunisation, Device Lot Number: F655, Device Expiration Date: 01May2027. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DEVICE CONNECTION ISSUE (non-serious), described as "the connection between the antigen vial and diluent syringe not going well"; POOR QUALITY DEVICE USED (non-serious), described as "other Abrysvo vaccines that had the connection between the antigen vial and diluent syringe not going well/ those were all administered to patients".  Causality for "the connection between the antigen vial and diluent syringe not going well" and "other abrysvo vaccines that had the connection between the antigen vial and diluent syringe not going well/ those were all administered to patients" was determined associated to device constituent of rsv vaccine prot.subunit pref 2v (malfunction).  Additional information: The reporter called that he had been having experiences with the connection between the antigen vial and diluent syringe which was not going well and he did have one yesterday (09Nov2023) that actually came apart and he wasted that dose. It was at the collar of the vial and looked to him like the collar had broken possibly and he couldn't quite tell but when putting the two together for the diluent syringe and vial and after connecting them and pushing the diluent syringe, it came apart completely and sometimes he noted the connection was not complete and it wanted to unscrew. The Abrysvo vaccine from yesterday that came apart was not administered to any patient. Lot number for yesterday one: Antigen vial: lot number HF5020, expiry date Feb2025. Vial Adaptor: lot number F655, expiry date 01May2027. Diluent syringe: lot is HA3217 with expiry date Mar2025. For the other Abrysvo vaccines that had the connection between the antigen vial and diluent syringe not going well and for the Abrysvo vaccines that want to come unscrewed, he was dealing with it and did not have an explanation on why they were trying to come unscrewed and he was able to deal with those and still operate with those using dexterity with his fingers and it keeps those vaccines viable and those were all administered to patients.   The information on the batch/lot number for rsv vaccine prot.subunit pref 2v has been requested and will be submitted if and when received.
One day following DTaP injection left lateral upper arm with positive edema,  2+ erythema, pain, warm to touch, cellulitis, 4" x 5.5" area of involvement; Treated: with Augmentin
Hypersensitivity local reaction, redness, itchy, warm to touch, small amount of bruising steroid cream given.
Information has been received from a physician concerning a four month old patient who was vaccinated with Rotateq. The patient received the first dose at two months of age and received an additional dose at four months. Subsequently the patient experienced vomiting one week after receiving Rotateq. Therapy with Rotateq was discontinued. Subsequently, the patient recovered from the vomiting. Additional information has been requested.
This spontaneous report as received from a pharmacist refers to a 65 year old female patient. On an unknown date in 2013, (reported as about a year ago), the patient was vaccinated with ZOSTAVAX. There were no concomitant medications, medical history or drug allergies. On an unknown date in 2013, the day after receiving the ZOSTAVAX, the patient experienced increased heart rate, redness, pain and slight swelling at the injection site, and shortness of breath. The patient stated that she had no history of cardiac problems or symptoms. No treatment was given for the events. The patient stated that she did not have an anaphylactic reaction. The patient did not seek medical attention for the events. The outcome of increased heart rate, redness, pain and slight swelling at the injection site and shortness of breath was reported as recovered/resolved on the same day. Additional information has been requested.
Patient experienced a seizure lasting 2-3 minutes approximately 1-2 minutes after receiving the vaccine. patient has a history of seizures/epilepsy.
It was reported in a published article, that a 41 year old female pt, with a strong family history of immune disorders, delivered a normal girl in 1987, was vaccinated with a booster dose of rubella virus vaccine live II in the postpartum period. Subsequently her next pregnancy ended in a miscarriage. The author noted that "vaccination of women around conception may lead to stillbirths, premature delivery and vanishing twins." Adverse outcomes associated with postpartum rubella or MMR vaccine. It was unknown if medical attention was sought. It was reported in a published article, title as stated above, that a 41 year old female patient, with a strong family history of immune disorders, delivered a normal girl in 1987, was vaccinated with a booser dose of rubella virus vaccine live (second generation) in the postpartum perious. Subsequently her next pregnancy ended in a miscarriage. The auther noted that "vaccination of women around conception may lead to sillbirths, premature delivery and "vanishing twins." According to the reporter one of the patient's sons had autism (WAES#0305USA00325) and another son had speech difficulties (WAES #0404USA000703). It was unknown if medical attention was sought.
On day 1 I experienced joint pain and hyperactivity for 24 hours, difficulty sleeping, very hyper alert. Day 9, woke up with severe vertigo with dizziness, nausea, and ear fullness.